Vanguard Group Inc Jounce Therapeutics, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.9 - $1.85 $426,714 - $877,134	474,127 Added 29.03%	2,107,305 $3.9 Million
Q4 2022 Feb 10, 2023	BUY	$0.64 - $1.99 $4,685 - $14,568	7,321 Added 0.45%	1,633,178 $1.81 Million
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $62,470 - $112,584	22,883 Added 1.43%	1,625,857 $3.8 Million
Q2 2022 Aug 12, 2022	SELL	$2.8 - $7.67 $29,486 - $80,772	-10,531 Reduced 0.65%	1,602,974 $4.86 Million
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $129,052 - $183,379	21,473 Added 1.35%	1,613,505 $11 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $1.06 Million - $1.43 Million	148,603 Added 10.3%	1,592,032 $13.3 Million
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $184,484 - $319,552	36,604 Added 2.6%	1,443,429 $10.7 Million
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $9.26 Million - $15 Million	1,406,825 New	1,406,825 $9.57 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.